Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

Name: Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.
Published: 2017
License: Public Domain

Octapharma · 2017

ClinicalTrials.gov · Datasets · License: Public Domain · 2017

Open Source ↗

significant bleeding risk, anticoagulant reversal, urgent surgery, invasive procedures, vitamin k, prothrombin complex concentrate, four-factor prothrombin complex concentrate (4f-pcc), interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

Related documents